|
Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis. |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; CTI; Incyte |
Research Funding - Celgene; CTI; Gilead Sciences; Incyte; Pfizer; Roche/Genentech |
|
|
Speakers' Bureau - Novartis; Pfizer |
Research Funding - Pfizer |
|
|
Consulting or Advisory Role - Celgene; Incyte; Novartis; Pfizer |
Speakers' Bureau - ARIAD; Celgene; Incyte; Novartis |
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); NS Pharma (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Celgene; Novartis |
|
|
Honoraria - ARIAD; Bristol-Myers Squibb; CTI; Galena Biopharma; Incyte; Novartis; Pfizer |
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; CTI; Incyte; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst) |
Expert Testimony - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - ARIAD; CTI; CTI; Galena Biopharma; Novartis; Pfizer |
|
|
Stock and Other Ownership Interests - Impact Biomedicines; Samumed |
Consulting or Advisory Role - Impact Biomedicines |
Research Funding - Celgene; GlaxoSmithKline; Johnson & Johnson |
Patents, Royalties, Other Intellectual Property - Forty Seven |
|
|
Honoraria - AOP Orphan Pharmaceuticals; Novartis; shire |
Consulting or Advisory Role - Baxalta; Galena Biopharma; Incyte; Novartis |
Research Funding - Celgene (Inst); CTI (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); NS Pharma (Inst); Pfizer (Inst); Pharmaessentia (Inst); Promedior (Inst) |
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Incyte; Novartis |
|
|
Consulting or Advisory Role - ERYTECH Pharma; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; Celgene; CTI; Gilead Sciences; Incyte; Novartis; Onconova Therapeutics |
|
|
Speakers' Bureau - Novartis; Shire |
|
|
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Exelixis; Fuji Pharma; Kowa; Kyowa Hakko Kirin; Lilly; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Shire; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Ono Pharmaceutical |
Research Funding - Amgen Astellas BioPharma; Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Nippon Shinyaku; Novartis Canada Pharmaceuticals Inc; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Toyama Chemical Co; Yakult Pharmaceutical |
|
|
Employment - Bristol-Myers Squibb; Pfizer |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Consulting or Advisory Role - CTI; Gilead Sciences; Incyte |
Research Funding - CTI; Gilead Sciences; Incyte; Pfizer |